retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide in adults with obesity

Patients with high A1c often achieve only about half the weight loss predicted for non-diabetics

Understanding when lifestyle modifications alone may be insufficient helps ensure appropriate and timely medical intervention

Retatrutide is not available on the NHS as it has not received MHRA marketing authorisation

FDA reportedly granted GRAS status for one specific oral formulation but not for the injectable peptide

Development of composite PLGA microspheres containing exenatide-encapsulated lecithin nanoparticles for sustained drug release

Compensation in Ozempic Vision Loss Cases Victims of Ozempic-related vision damage may be eligible for various types of compensation